Merck Serono Is Hoping It Pays To Plan Ahead With New Phase III Trial For Tecemotide
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck Serono will conduct a second Phase III study of lung cancer vaccine tecemotide in patients treated concurrently with chemotherapy and radiation. The START trial, which also dosed patients receiving sequential therapy, failed but the predefined, concurrently treated subgroup showed greater median overall survival compared to placebo.
You may also be interested in...
Where Merck KGAA’s Pipeline Stands
Pipeline review resulted in new focus and products with high value, exec explains.
Merck Serono Says Partnering Part Of Its Future, Seeks Anti-PD-L1 Deal
Mid-sized German pharma says partnering will be part of its future, as it progresses three key pipeline assets and initiates talks with big pharma players wanting to partner its anti-PD-L1 compound.
Merck Serono Says Partnering Part Of Its Future, Seeks Anti-PD-L1 Deal
Mid-sized German pharma says partnering will be part of its future, as it progresses three key pipeline assets and initiates talks with big pharma players wanting to partner its anti-PD-L1 compound.